5-HT1A receptor agonist
- 5-HT1A receptor agonist
- 5-HT1A receptor agonist (high affinity)
- 5-HT1A receptor agonist (strongest binding affinity)
- 5-HT1A receptor preferring agonist

5-HT1A receptor full agonist
- 5-HT1A receptor full agonist

5-HT1A receptor partial agonist
- 5-HT1A receptor partial agonist

5-HT2A receptor agonist
- 5-HT2A receptor agonist
- 5-HT2A receptor agonist (DMT component)
- 5-HT2A receptor agonist (primary)
- 5-HT2A receptor full agonist

5-HT2A receptor agonist (potent)
- 5-HT2A receptor agonist (potent)
- 5-HT2A receptor agonist (potent, pEC50 9.43)

5-HT2A receptor agonist (speculated)
- possible 5-HT2A receptor agonist (speculated)

5-HT2A receptor antagonist
- 5-HT2A receptor antagonist

5-HT2A receptor partial agonist
- 5-HT2A receptor agonist (partial)
- 5-HT2A receptor partial agonist
- 5-HT2A receptor partial agonist (5-8 times greater affinity than mescaline)
- 5-HT2A receptor partial agonist (low potency)
- 5-HT2A receptor partial agonist (weak)

5-HT2B receptor agonist
- 5-HT2B receptor agonist

5-HT2B receptor agonist (cardiotoxic)
- 5-HT2B receptor agonist (cardiotoxic)

5-HT2B receptor partial agonist
- 5-HT2B receptor partial agonist
- 5-HT2B receptor partial agonist (moderate-efficacy)

5-HT2C receptor agonist
- 5-HT2C receptor agonist
- 5-HT2C receptor agonist (pKi 7.8)

5-HT2C receptor full agonist
- 5-HT2C receptor full agonist

5-HT2C receptor partial agonist
- 5-HT2C partial agonist
- 5-HT2C receptor partial agonist
- 5-HT2C receptor partial agonist (high-efficacy)

5-HT6 receptor agonist
- 5-HT6 receptor agonist

Acetylcholine precursor
- Acetylcholine precursor
- converts to dopamine, norepinephrine, and epinephrine (catecholamines)
- Enhanced high-affinity choline uptake (HACU) in the hippocampus
- enhances acetylcholine synthesis via cholinergic pathways
- increased acetylcholine synthesis
- increases acetylcholine synthesis and release via enhanced choline availability
- Precursor to choline and glycerophosphate in the brain
- supports catecholamine neurotransmitter synthesis
- DMAE is converted to choline which serves as a precursor for acetylcholine synthesis

Acetylcholinesterase inhibitor
- Acetylcholinesterase inhibitor

Adenosine receptor antagonist
- Adenosine receptor antagonist
- Adenosine receptor antagonist (competitive inhibitor)

Adrenergic receptor agonist
- adrenergic alpha-1 receptor agonist
- Adrenergic receptor agonist
- at high doses affects norepinephrine receptors
- Indirect adrenergic agonist

AMPA receptor modulator
- AMPA receptor modulator (via glutathione)

AMPA receptor negative allosteric modulator
- AMPA glutamate receptor antagonist

AMPA receptor positive allosteric modulator
- AMPA receptor positive allosteric modulator

Androgen receptor agonist
- Androgen receptor agonist

Anti-parkinsonian
- anti-parkinsonian

Aromatase inhibitor
- Aromatase inhibitor

Beta-adrenergic receptor antagonist
- Beta-adrenergic receptor antagonists

CB1 and CB2 receptor agonist (speculated)
- Possible CB1 cannabinoid receptor agonist (speculated)

CB1 and CB2 receptor full agonist
- CB1 and CB2 receptor full agonist
- CB1 cannabinoid receptor full agonist (Ki 0.9 nM, EC50 1.8 nM)
- CB1 cannabinoid receptor full agonist (Ki 5.84 nM)
- CB1 receptor full agonist
- CB2 cannabinoid receptor full agonist (Ki 23.2 nM, EC50 3.2 nM) with selectivity for CB2
- CB2 cannabinoid receptor full agonist (Ki 4.57 nM, with slight selectivity)
- CB2 receptor full agonist (5x lower affinity than CB1)

CB1 and CB2 receptor partial agonist
- CB1 and CB2 receptor partial agonist

Central nervous system depressant
- Central nervous system depressant

Combination mechanism
- Combination mechanism
- Multi-target modulator
- Multiple receptor antagonist

Cytochrome P450 3A4 inhibitor
- Cytochrome P450 3A4 inhibitor

Cystine-glutamate antiporter substrate
- Cystine-glutamate antiporter substrate

D2 dopamine receptor agonist
- Dopamine receptor agonist

D2 dopamine receptor agonist (weak)
- D2 dopamine receptor agonist (weak)
- D2 receptor agonist (through LSD metabolite)

Deliriant (uncertain mechanism)
- Deliriant (uncertain mechanism)

Dopamine receptor agonist (low affinity)
- dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)

Dopamine releasing agent
- Dopamine releaser
- dopamine releaser and reuptake inhibitor
- dopamine reuptake inhibitor and releaser
- dopamine transporter phosphorylation (increases extracellular dopamine)
- weak dopamine releaser

Dopamine releasing agent and reuptake inhibitor
- Dopamine releasing agent and reuptake inhibitor

Dopamine reuptake inhibitor
- Atypical dopamine reuptake inhibitor
- blocks dopamine transporter (DAT IC50: 0.79 nM)
- Dopamine reuptake inhibitor
- dopamine reuptake inhibitor (weak)

Dopamine synthesis enhancer
- Dopamine synthesis enhancer

Dopamine-norepinephrine releasing agent
- Dopamine-norepinephrine releasing agent
- increases dopamine and norepinephrine levels in CNS
- monoamine releasing agent

Dopamine-norepinephrine reuptake inhibitor
- approximately 1.85 times more selective for norepinephrine than dopamine
- Dopamine-norepinephrine reuptake inhibitor
- dopamine-noradrenaline reuptake inhibitor
- Norepinephrine-dopamine reuptake inhibitor (NDRI)

Dopamine-norepinephrine reuptake inhibitor (potent)
- Dopamine-norepinephrine reuptake inhibitor (potent)

Estrogen receptor agonist
- Estrogen receptor agonist

G-protein-biased μ-opioid receptor agonist (partial)
- G-protein-biased μ-opioid receptor agonist (partial)
- G-protein-biased μ-opioid receptor agonists

GABA-A receptor agonist
- Gamma-aminobutyric acid type A receptor agonist

GABA-A receptor agonist (at high concentration)
- Gamma-aminobutyric acid type A receptor agonist (at high concentration)

GABA-A receptor agonist (stereoselective)
- Gamma-aminobutyric acid type A receptor agonist (stereoselective)

GABA-A receptor positive allosteric modulator
- enhances GABA efficiency and effects
- Full agonist at benzodiazepine/GABA-A receptor
- GABA-A receptor positive allosteric modulator
- GABA-A receptor potentiation
- Gamma-aminobutyric acid type A receptor positive allosteric modulator
- increases chloride channel opening frequency when GABA is present

GABA-A receptor positive allosteric modulator (barbiturate site)
- GABAA receptor positive allosteric modulator (binds to barbiturate site, increases chloride ion pore opening duration)
- increases duration of chloride ion channel opening

GABA-A receptor positive allosteric modulator (benzodiazepine site)
- Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)
- GABA-A receptor positive allosteric modulator (increases frequency of chloride channel opening)
- GABA-A receptor positive allosteric modulator (preferential affinity for alpha-1, alpha-3, and alpha-5 subunits)

GABA-A receptor positive allosteric modulator (non-benzodiazepine site)
- GABAA receptor positive allosteric modulator (binds to distinct site from benzodiazepines)
- Gamma-aminobutyric acid type A receptor positive allosteric modulator (non-benzodiazepine site)

GABA-A receptor positive allosteric modulator (proconvulsant site)
- GABA-A receptor positive allosteric modulator (binds to proconvulsant site)

GABA-B receptor agonist
- Gamma-aminobutyric acid type B receptor agonist

Gamma-hydroxybutyrate receptor agonist
- Gamma-hydroxybutyrate receptor agonist

Glutamate receptor modulator
- Glutamate receptor modulator

Glutathione precursor
- Glutathione precursor
- stimulates glutathione synthesis

Glycine receptor positive allosteric modulator
- glycine receptor potentiation

H1 histamine receptor antagonist
- H1 histamine receptor antagonist
- H1 histamine receptor antagonist via promethazine
- Histamine H1 receptor antagonist

H1 histamine receptor inverse agonist
- H1 histamine receptor inverse agonist

Imidazoline receptor agonist
- Imidazoline receptor agonist

Melatonin receptor agonist
- Melatonin receptor agonist

Metabotropic glutamate receptor agonist
- Metabotropic glutamate receptor agonist
- mGluR2/3 receptor agonist (indirect)

Methyl group donor
- facilitates trimethylamine (betaine) production for osmoregulation and SAM-e synthesis
- Methyl group donor in neurotransmitter synthesis

Monoamine oxidase B inhibitor
- Monoamine oxidase B inhibitor

Monoamine oxidase inhibitor
- may inhibit MAO-A and MAO-B
- Monoamine oxidase inhibitor
- possible monoamine oxidase inhibition
- potential MAOI properties
- potent MAO-A inhibitor (IC50 400 nM)
- potent reversible MAO-A inhibitor (IC50 ~1700 nM)
- reversible monoamine oxidase-A inhibitor (harmala alkaloids)
- weak monoamine oxidase inhibitor

Mood stabilizer
- Mood stabilizer

Muscarinic acetylcholine receptor agonist
- Muscarinic acetylcholine receptor agonist

Muscarinic acetylcholine receptor antagonist
- Competitive antagonist at muscarinic acetylcholine receptors M1 and M2 (anticholinergic)
- Muscarinic acetylcholine receptor antagonist

N-methyl-D-aspartate receptor agonist
- N-methyl-D-aspartate receptor agonist

NF-kB inhibitor
- NF-kB inhibitor

Nicotinamide methyltransferase substrate
- converts nicotinamide to N-methyl-nicotinamide

Nicotinic acetylcholine receptor agonist
- Nicotinic acetylcholine receptor agonist

Nicotinic acetylcholine receptor antagonist
- nACh receptor antagonist (beta2-subunit)
- potent nicotinic acetylcholine antagonist

Nitric oxide activity enhancer
- increased nitric oxide activity (cerebral blood flow enhancement)

NMDA receptor antagonist
- NMDA receptor antagonist
- NMDA receptor antagonist (primary)

NMDA receptor antagonist (noncompetitive)
- NMDA receptor antagonist (noncompetitive)

NMDA receptor antagonist (selective)
- NMDA receptor antagonist (selective ligand without appreciable dopamine transporter affinity)

NMDA receptor modulator
- NMDA receptor modulator (via glutathione)

Nociceptin receptor agonist
- Nociceptin receptor agonist with μ-opioid receptor affinity

Nootropic (uncertain mechanism)
- Nootropic (uncertain mechanism)

Norepinephrine releasing agent
- minor norepinephrine releasing agent
- norepinephrine releaser
- Norepinephrine releasing agent

Norepinephrine releasing agent and reuptake inhibitor
- norepinephrine releaser and reuptake inhibitor
- Norepinephrine releasing agent and reuptake inhibitor
- norepinephrine reuptake inhibitor and releaser

Norepinephrine reuptake inhibitor
- blocks norepinephrine transporter (NET IC50: 17.96 nM)
- Norepinephrine reuptake inhibitor
- Norepinephrine reuptake inhibitor (likely triple monoamine reuptake inhibitor)
- norepinephrine reuptake inhibitor (metabolite norpethidine is a serotonin reuptake inhibitor)
- norepinephrine reuptake inhibitor (weak)

Phosphocreatine source
- releases phosphate to regenerate ATP during periods of stress or high-intensity exercise
- Stores high-energy phosphate groups as phosphocreatine (creatine phosphate)

Phospholipid synthesis enhancer
- cytidine converts to uridine enhancing phosphatidylcholine synthesis
- supports phospholipid biosynthesis and cell membrane integrity
- supports phospholipid synthesis for cell membrane structure

Phospholipase modulator
- Activates phospholipase A2 instead of phospholipase C

Potassium channel opener
- Potassium channel opener
- two-pore-domain K+ channel activation

Precursor to L-DOPA
- Precursor to L-DOPA

Prodrug (4-HO-MiPT)
- 5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)

Prodrug (6-monoacetylmorphine)
- prodrug of 6-monoacetylmorphine

Prodrug (choline)
- Metabolizes to choline and cytidine

Prodrug (cytidine)
- Metabolizes to choline and cytidine

Prodrug (dihydromorphine)
- prodrug of dihydromorphine

Prodrug (DMAE)
- Metabolizes into DMAE and pCPA

Prodrug (levorphanol)
- prodrug of levorphanol

Prodrug (LSD)
- acts as prodrug for LSD via deacylation
- prodrug of LSD

Prodrug (morphine)
- Mu-opioid receptor agonist (as morphine after first-pass metabolism)
- Mu-opioid receptor agonist (via active metabolite morphine)
- prodrug metabolized by CYP2D6 to morphine
- prodrug of morphine
- prodrug of morphine via codiene

Prodrug (muscimol)
- Prodrug to muscimol (gamma-aminobutyric acid type A receptor agonist)

Prodrug (O-desmethyltramadol)
- active metabolite of tramadol
- prodrug of O-desmethyltramadol

Prodrug (pCPA)
- Metabolizes into DMAE and pCPA

Prodrug (psilocin)
- 5-HT1A receptor agonist (psilocin acts as prodrug)
- prodrug of psilocin

Prodrug (R-4618)
- prodrug of R-4618

Prostaglandin synthetase inhibitor
- prostaglandin synthetase inhibitor

Serotonin 5-HT3 receptor antagonist
- Serotonin 5-HT3 receptor antagonist

Serotonin receptor agonist
- affects dopamine, acetylcholine, and serotonin receptors
- Serotonin receptor agonist

Serotonin receptor partial agonist
- Serotonin receptor agonist (partial)

Serotonin releasing agent
- Selective serotonin releasing agent (SSRA)
- serotonin releaser
- Serotonin releasing agent

Serotonin releasing agent (weak)
- serotonin releasing agent (weak)

Serotonin releasing agent and reuptake inhibitor
- Serotonin releaser and reuptake inhibitor
- Serotonin releasing agent and reuptake inhibitor
- Serotonin reuptake inhibitor and releaser

Serotonin reuptake and receptor modulator
- Serotonin reuptake and receptor modulators

Serotonin reuptake inhibitor
- blocks serotonin transporter (SERT IC50: 3.13 nM)
- selective serotonin reuptake inhibitor (SSRI)
- serotonin reuptake inhibitor

Serotonin reuptake inhibitor (weak)
- minimal serotonin activity
- Serotonin reuptake inhibitor (weak)
- weak serotonin reuptake inhibition
- weak serotonin reuptake inhibitor

Serotonin-dopamine-norepinephrine releasing agent
- increases serotonin, dopamine, and norepinephrine activity
- Serotonin-dopamine-norepinephrine releasing agent
- Serotonin-norepinephrine-dopamine releasing agent (SNDRA)

Serotonin-dopamine-norepinephrine reuptake inhibitor
- Monoamine triple reuptake inhibitor (dopamine, norepinephrine, serotonin)
- Serotonin-dopamine-norepinephrine reuptake inhibitor
- Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI)

Serotonin-norepinephrine releasing agent
- Serotonin-norepinephrine releasing agent (SNRA)

Serotonin-norepinephrine reuptake inhibitor
- serotonin-norepinephrine reuptake inhibitor

Sigma-1 receptor agonist
- sigma receptor agonist
- Sigma-1 receptor agonist

Sodium channel blocker
- sodium channel blockade
- Sodium channel blockers

Stimulant (uncertain mechanism)
- Stimulant (uncertain mechanism)

TAAR1 agonist
- TAAR1 agonist
- Trace amine receptor agonist

Unclear mechanism
- does not bind to monoamine transporters
- mechanism underlying hallucinogenic effects remains unstudied
- metabolized by CYP2D6 and CYP3A4
- suspected mu-opioid receptor affinity
- to a lesser extent affects epinephrine, glutamate, and cortisol
- Uncertain mechanism

VMAT2 inhibitor
- VMAT2 inhibitor

Voltage-gated calcium channel alpha-2-delta subunit ligand
- Voltage-gated calcium channel alpha-2-delta subunit ligand

Voltage-gated potassium channel blocker
- voltage-gated potassium channel blockade

δ-opioid receptor agonist
- delta-opioid receptor agonist (weak)

δ-opioid receptor antagonist
- δ-opioid receptor antagonist

κ-opioid receptor agonist
- Kappa-opioid receptor agonist
- kappa-opioid receptor agonist (weak)
- κ-Opioid receptor agonist

κ-opioid receptor antagonist
- κ-opioid receptor antagonist

μ-Opioid receptor agonist
- Mu-opioid receptor agonist
- mu-opioid receptor agonist (selective)
- Mu-opioid receptor agonist (highly selective)
- Mu-opioid receptor agonists
- μ-Opioid receptor agonist
- Opioid receptor agonist (limited data)

μ-Opioid receptor agonist (full)
- μ-Opioid receptor agonist (full)

μ-Opioid receptor agonist (limited data)
- μ-Opioid receptor agonist (limited data)

μ-Opioid receptor agonist (partial)
- μ-Opioid receptor agonist (partial)

μ-Opioid receptor agonist (peripherally-restricted)
- μ-Opioid receptor agonist (peripherally-restricted)

μ-Opioid receptor antagonist
- μ-opioid receptor antagonist
